Tela Bio, Inc. - TELA STOCK NEWS

MALVERN, Pa., June 14, 2021 – TELA Bio, Inc. (NASDAQ: TELA) announced its participation in the JMP Securities Life Sciences Conference. The presentation is scheduled for June 16, 2021, at 11:30 AM EDT. Interested parties can access the live and archived webcast at ir.telabio.com. TELA Bio focuses on innovative tissue reinforcement materials for soft tissue reconstruction, aiming to enhance clinical outcomes and minimize the use of permanent synthetic materials.

TELA Bio, Inc. (NASDAQ: TELA) announced the appointment of John Nosenzo, former Chief Commercial Officer at Bioventus Inc., to its board of directors, effective June 2, 2021. This change coincides with the departure of board member Adele Olivia, resulting in a board of seven directors, six of whom are independent. Nosenzo brings extensive healthcare marketing and sales experience, which could positively impact TELA's strategic direction. The company focuses on innovative tissue reinforcement materials for soft tissue reconstruction, aiming to improve clinical outcomes.

TELA Bio, Inc. (NASDAQ: TELA) has appointed Marissa Conrad as Vice President of Clinical and Regulatory Affairs, effective May 24, 2021. With over 16 years of experience in R&D, clinical, and regulatory roles in the medtech industry, she will oversee clinical and regulatory strategies for TELA's current and future products. CEO Antony Koblish praised her as a valuable asset, highlighting her strong track record and leadership skills. TELA Bio aims to enhance soft tissue reconstruction solutions through its innovative products, such as OviTex®.

TELA Bio, Inc. (NASDAQ: TELA), a medical technology company focused on innovative tissue reinforcement materials, will participate in two investor conferences. The management will present at the UBS Global Healthcare Virtual Conference on May 24, 2021, at 8:00 AM EST. The Jefferies Virtual Healthcare Conference is scheduled for June 3, 2021, at 3:30 PM EST. Both presentations will be accessible via the company’s investor relations website. TELA Bio aims to enhance clinical outcomes in soft tissue reconstruction with its OviTex® products.

TELA Bio, Inc. (NASDAQ: TELA) has launched the BRAVO II study to evaluate the clinical performance of OviTex® Reinforced Tissue Matrices in robotic ventral hernia repairs. The first patient was enrolled at St. Luke's Hospital in Kansas. This study aims to enroll up to 100 subjects across seven US sites, focusing on early postoperative complications and long-term hernia recurrence. CEO Antony Koblish expressed commitment to enhancing surgical materials, while Dr. Geoffrey Slayden highlighted the advantages of using reinforced tissue matrices in robotic procedures.

TELA Bio, Inc. (Nasdaq: TELA) reported strong financial results for Q1 2021, achieving revenue of $5.9 million, a 58% increase from Q1 2020. Despite challenges from COVID-19, the company saw high utilization of its OviTex LPR product line, marking the highest volume quarter for these products. Gross profit remained stable at 59% of revenue. Operating expenses rose to $10.7 million, resulting in a net loss of $8.1 million for the quarter. For the full year, TELA maintains a revenue guidance of $27-30 million, reflecting a growth of 48-65% year-over-year.

TELA Bio, Inc. is set to report its first quarter financial results for the period ending March 31, 2021, on May 13, 2021. The company's management will hold a conference call and webcast at 4:30 p.m. ET to discuss these results and provide a corporate update. TELA Bio focuses on innovative tissue reinforcement materials designed for soft tissue reconstruction, aiming to offer effective biologic material repair solutions and improve clinical outcomes. The company is committed to addressing unmet needs in hernia repair, abdominal wall reconstruction, and plastic and reconstructive surgery.

TELA Bio reported fourth quarter revenue of $5.7 million, an increase of 17% year-over-year, and full-year revenue of $18.2 million, up 18% from 2019. Gross profit for Q4 was $3.7 million (65% margin), and $11.2 million (62% margin) for the full year. Operating expenses rose to $10.4 million in Q4 and $36.5 million annually, leading to net losses of $7.8 million and $28.8 million, respectively. For 2021, TELA projects revenue between $27.0 million and $30.0 million, indicating growth of 48% to 65%.

TELA Bio, a medical technology company, has reported encouraging findings from the 12-month analysis of its BRAVO study on OviTex Reinforced Tissue Matrix for ventral hernia treatment. Out of 76 patients, only two experienced a recurrence at the surgical site, while interim results at 24 months showed no recurrences among the 51 patients followed. The results demonstrate low postoperative complications, and the data have been submitted for journal publication. TELA anticipates completing the BRAVO trial this year, highlighting OviTex's potential in hernia repair.